Biotech entity

Kansas

Company

Kansas is most often covered alongside CNBC, which appears in 1 of these 2 stories. Across a 27-day span, the pace is roughly 0.5 stories per week. The clearest coverage concentration is fda-approval: 1 of 2 stories, with the rest divided among 1 other category.

Last mentioned: Aug 16, 2026

Entity pulse

Recent coverage · Kansas

2 stories
6.5 avg impact
0% positive
100% negative

Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.

  • 100% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Kansas

Kansas is most often covered alongside CNBC, which appears in 1 of these 2 stories. Across a 27-day span, the pace is roughly 0.5 stories per week. The clearest coverage concentration is fda-approval: 1 of 2 stories, with the rest divided among 1 other category. Their average consequence score of 6.5 runs above the beat's 5.9 for that window. They are less corroborated than the beat average, carrying 2 original sources each against 2.3 for the same window. We currently track 2 Biotech stories that mention Kansas, published between July 21, 2026 and August 16, 2026.

Stories tracked
2
Per week
0.5
Sources per story
2

Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 174 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Kansas. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning Kansas 2

Kansas is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.